GlaxoSmithKline's cervical cancer vaccine highly immunogenic, well-tolerated in trial

New York, June 5 - GlaxoSmithKline said the first data from a clinical trial examining the immune response in women aged 26-55 demonstrated that Cervarix, its cervical cancer candidate vaccine, is highly immunogenic and well-tolerated.

The data was presented at the American Society of Clinical Oncology annual meeting in Atlanta.

In the phase 3 study, all women across all study age groups (15-55 years of age) vaccinated with GlaxoSmithKline's cervical cancer candidate vaccine demonstrated antibody response against HPV 16 and HPV 18 - the two most common cancer-causing HPV types - one month after completion of the vaccination course.

All women remained seropositive when evaluated at 12 months after the first dose, with antibody levels substantially higher than those reported following natural infection.

These new results suggest that women over 25 years old could also be protected from infection with HPV types 16 and 18 through vaccination, the company said.

Based in London, GlaxoSmithKline is a research-based pharmaceutical and health care company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.